Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

[1]  P. Rosenstiel,et al.  Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease. , 2005, Gut.

[2]  C. Brensinger,et al.  A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. , 2004, Gastroenterology.

[3]  G. Corazza,et al.  Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease , 2003, Gut.

[4]  D. Hommes,et al.  Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.

[5]  D. Hommes,et al.  Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets , 2003, Gut.

[6]  S. Hanauer.  Maintenance infliximab for Crohn's disease , 2002, The Lancet.

[7]  Philip Rosenstiel,et al.  p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease1 , 2002, The Journal of Immunology.

[8]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[9]  T. van der Poll,et al.  Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia1 , 2002, The Journal of Immunology.

[10]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[11]  M. Peppelenbosch,et al.  Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis , 2002, Gut.

[12]  D. Hommes,et al.  Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. , 2002, Gastroenterology.

[13]  A. Zinsmeister,et al.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.

[14]  J. Avruch,et al.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.

[15]  P. Rutgeerts,et al.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. , 2000, Gastroenterology.

[16]  S. Nikolaus,et al.  Mechanisms in failure of infliximab for Crohn's disease , 2000, The Lancet.

[17]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[18]  S. Bakos,et al.  Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. , 1999 .

[19]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[20]  F. Dumont,et al.  A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: dependence on CD28 signaling and preferential inhibition of IL-10 production. , 1999, Cellular immunology.

[21]  J. Hampe,et al.  Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease , 1999, The Lancet.

[22]  S. Murch,et al.  Local and systemic effects of macrophage cytokines in intestinal inflammation. , 1998, Nutrition.

[23]  S. Hanauer,et al.  A safety and efficacy study of recombinant human interleukin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn's disease (CACD) , 1998 .

[24]  P. Rutgeerts,et al.  Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. , 1998, Gastroenterology.

[25]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[26]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[27]  R. Coffman,et al.  Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. , 1994, Immunity.

[28]  J. Rochon,et al.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.

[29]  T. Macdonald,et al.  Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. , 1993, Gut.

[30]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[31]  R. Macdermott,et al.  Enhand secretion of tumour necrosis factor‐alpha, IL‐6, and IL‐1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease , 1993 .

[32]  C. Nast,et al.  Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. , 1992, Gastroenterology.

[33]  J Y Mary,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.

[34]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.